Insulet Co. (PODD) Receives Average Recommendation of “Buy” from Brokerages

Insulet Co. (NASDAQ:PODD) has been assigned a consensus recommendation of “Buy” from the thirteen brokerages that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $103.80.

A number of equities analysts have commented on the stock. BidaskClub downgraded shares of Insulet from a “hold” rating to a “sell” rating in a research note on Friday, April 19th. BTIG Research upgraded shares of Insulet from a “neutral” rating to a “buy” rating and set a $115.00 price objective on the stock in a research note on Monday, May 6th. Oppenheimer set a $100.00 price objective on shares of Insulet and gave the company a “hold” rating in a research note on Tuesday, February 26th. Canaccord Genuity reiterated a “buy” rating and set a $110.00 price objective (up from $100.00) on shares of Insulet in a research note on Monday, May 6th. Finally, Northland Securities reiterated a “buy” rating and set a $100.00 price objective on shares of Insulet in a research note on Tuesday, February 26th.

PODD stock traded up $2.47 during mid-day trading on Tuesday, reaching $111.79. The company had a trading volume of 312,344 shares, compared to its average volume of 696,052. The company has a debt-to-equity ratio of 2.68, a current ratio of 4.36 and a quick ratio of 3.71. The company has a market capitalization of $6.67 billion, a P/E ratio of 2,235.80 and a beta of 1.12. Insulet has a 12 month low of $70.80 and a 12 month high of $112.49.

Insulet (NASDAQ:PODD) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.05. The business had revenue of $159.56 million for the quarter, compared to the consensus estimate of $154.66 million. Insulet had a net margin of 2.37% and a return on equity of 7.01%. The company’s revenue for the quarter was up 29.1% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.11) EPS. On average, research analysts expect that Insulet will post 0.26 EPS for the current fiscal year.

In related news, SVP David Colleran sold 7,395 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $94.89, for a total transaction of $701,711.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Shacey Petrovic sold 1,066 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $92.64, for a total transaction of $98,754.24. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 96,809 shares of company stock worth $9,696,382. Insiders own 3.50% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Teachers Advisors LLC raised its holdings in shares of Insulet by 105.8% in the third quarter. Teachers Advisors LLC now owns 326,021 shares of the medical instruments supplier’s stock worth $34,542,000 after buying an additional 167,598 shares during the last quarter. Vanguard Group Inc raised its holdings in shares of Insulet by 1.7% in the third quarter. Vanguard Group Inc now owns 5,053,657 shares of the medical instruments supplier’s stock worth $535,434,000 after buying an additional 84,209 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Insulet by 8.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,873 shares of the medical instruments supplier’s stock worth $307,000 after buying an additional 305 shares during the last quarter. State Board of Administration of Florida Retirement System raised its holdings in shares of Insulet by 4.3% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 78,407 shares of the medical instruments supplier’s stock worth $6,219,000 after buying an additional 3,226 shares during the last quarter. Finally, Janney Montgomery Scott LLC raised its holdings in shares of Insulet by 3.7% in the fourth quarter. Janney Montgomery Scott LLC now owns 61,148 shares of the medical instruments supplier’s stock worth $4,850,000 after buying an additional 2,178 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Further Reading: Diversification For Individual Investors

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply